BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
6/14/2024 9:10:00 AM | Browse: 95 | Download: 226
 |
Received |
|
2023-12-27 04:12 |
|
Peer-Review Started |
|
2023-12-27 04:12 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2024-01-07 12:59 |
|
Revised |
|
2024-01-20 14:05 |
|
Second Decision |
|
2024-02-27 03:20 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2024-02-27 07:12 |
|
Articles in Press |
|
2024-02-27 07:12 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2024-05-27 07:11 |
|
Publish the Manuscript Online |
|
2024-06-14 09:10 |
| ISSN |
2222-0682 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Endocrinology & Metabolism |
| Manuscript Type |
Minireviews |
| Article Title |
Non-alcoholic fatty liver disease in type 2 diabetes: Emerging evidence of benefit of peroxisome proliferator-activated receptors agonists and incretin-based therapies
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Subhodip Pramanik, Partha Pal and Sayantan Ray |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Sayantan Ray, MBBS, MD, Assistant Professor, N/A, N/A, Department of Endocrinology, All India Institute of Medical Sciences, Bhubaneswar, Sijua, Patrapada, Bhubaneswar 751019, Odisha, India. sayantan.ray30@gmail.com |
| Key Words |
Non-alcoholic fatty liver disease; Type 2 diabetes; evidence; PPAR agonists; Incretin-based therapies |
| Core Tip |
Co-existence of non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM) synergistically act to increase the risk of adverse hepatic and extra hepatic outcomes. T2DM is an established risk factor for NAFLD progression to NASH, advanced fibrosis or cirrhosis. Timely intervention in these populations could have a significant effect on liver- related outcomes. Newer dual and pan-PPAR agonists show promising results in patients with NAFLD/NASH and T2DM. Incretin-based therapy for the treatment of NAFLD is currently being explored. With better understanding of the complex interaction between T2DM and NAFLD, PPAR agonists and incretin-based therapies are likely to provide more effective approach of NAFLD management in T2DM |
| Publish Date |
2024-06-14 09:10 |
| Citation |
<p>Pramanik S, Pal P, Ray S. Non-alcoholic fatty liver disease in type 2 diabetes: Emerging evidence of benefit of peroxisome proliferator-activated receptors agonists and incretin-based therapies. <i>World J Methodol</i> 2024; 14(2): 91319</p> |
| URL |
https://www.wjgnet.com/2222-0682/full/v14/i2/91319.htm |
| DOI |
https://dx.doi.org/10.5662/wjm.v14.i2.91319 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
